



Influenza Reagent
Influenza Virus Infectious SAN-049A (A/Michigan/105/2025)
NIBSC code: 25/326
Instructions for use
(Version 3.0, Dated 30/03/2026)

§

1. INTENDED USE

Reagent 25/326 was prepared from SAN-049A (H3N2), a reassortant of A/Michigan/105/2025 (H3N2) and PR/8/34 (H1N1), which was processed in 250µL volumes as liquid stock. The derivation and known passage history of 25/326 are attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material.

4. CONTENTS

Country of origin of biological material: United Kingdom.
Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

5. STORAGE

Store in the dark at -70°C or below.
Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

Ready to use.

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

N/A.

10. ACKNOWLEDGEMENTS

N/A.

11. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
<http://www.who.int/biologicals/en/>
JCTLM Higher order reference materials:
<http://www.bipm.org/en/committees/jc/jctlm/>
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
<http://www.nibsc.org/products/ordering.aspx>
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: Clear liquid	Corrosive: No
Stable: Yes	Oxidising: No
Hygroscopic: No	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other live influenza virus (specify):	
Toxicological properties	
Effects of inhalation:	Likelihood of influenza virus infection
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	



15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
Net weight: 0.25g
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable.
Attached: No

Passage history of SAN-049A (A/Michigan/105/2025) (H3N2)

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E3	E3	Lot#: 3032562757	CDC, USA
E13	E3/E10	Lot#: SP-2026-049A	Sanofi, USA
E14	E3/E10/E1	49930*	MHRA, UK

* The HA titre of this virus using 0.7% guinea pig red blood cells in 20 mM Oseltamivir is 1024. The infectious titre is unknown.

Sterility: No visible contamination was detected in a variety of media (tryptone soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus are available at GISAID with the accession number EPI_ISL_20401131.



sanofi

sanofi

Derivation Report

A/Michigan/105/2025

SAN-049A

H3N2 High Growth Reassortant

1



Derivation of SAN-049A

A/Michigan/105/2025 High Growth Reassortant

A/Michigan/105/2025 (SAN-049A) is an H3N2 high growth reassortant influenza virus.

A/Michigan/105/2025 (SAN-049A) is an H3N2 high growth reassortant influenza virus developed in Sanofi Flu Reassortant Lab, department Egg & Baculo Flu Platform at Sanofi, US.

Sanofi Lot #: SP-2026-049A

Wildtype Virus:

A/Michigan/105/2025 (the virus isolate was obtained from the CDC)

CDC Lot#: 3032562757

Passage # from CDC: Spf2E1

Donor Virus:

A/Puerto Rico/8/1934 (SP Lot # Batch 2)

Eggs:

Specific Pathogen Free (SPF) premium eggs were used for all passages.

Antiserum:

Rabbit antisera raised against influenza virus A/Puerto Rico/8/1934 was used in the process (SP Lot # SAN-Ab-019).



Passage History

	Wild-Type amplification	A/Michigan/105/2025 (H3N2) wild type virus @ 10^{-5}	HA titer: 1280
		↓	
	Co-infection passage	A/Michigan/105/2025 (H3N2) wild type virus @ 10^{-3} x A/Puerto Rico/8/1934 (H3N2) @ 10^{-6}	HA titer: 10240
		↓	
1	1 st antiserum passage	Inoculum with A/Puerto Rico/8/1934 HANA antibodies @ 1:75 dilution	HA titer: 1280
		↓	
2	2 nd antiserum passage	Inoculum with A/Puerto Rico/8/1934 HANA antibodies @ 1:75 dilution	HA titer: 1280
		↓	
3	3 rd antiserum passage/ 1 st limiting dilution passage	Inoculum @ 10^{-2} with A/Puerto Rico/8/1934 HANA antibodies @ 1:75 dilution and diluted 10^{-3}	HA titer: 5120
		↓	
4	2 nd limiting dilution passage	Inoculum @ 10^{-7} dilution	HA titer: 5120
		↓	
5	3 rd limiting dilution passage	Inoculum @ 10^{-8} dilution	HA titer: 20480
		↓	
6	4 th limiting dilution passage	Inoculum @ 10^{-8} dilution	HA titer: 5120
		↓	
7	5 th limiting dilution passage	Inoculum @ 10^{-8} dilution	HA titer: 2560
		↓	
8	Final amplification	Inoculum @ 10^{-5} dilution	HA titer: 10240

Passages prior to receipt from the CDC = 3

Total number of passages post co-infection= 8



Testing of A/Michigan/105/2025 (H3N2) SAN-049A

Test		Results																											
Sterility		No growth on Thioglycolate Medium and Trypticase Soy Broth after 10 days.																											
Infectivity		10 ^{9.1} EID ₅₀ / mL																											
Antigenic Testing	1-Way HAI	Passed																											
	2-Way HAI	Pending																											
Gene Ratio Determined by qPCR and confirmed by NGS.		5:3 reassortant HA, NA & PB1 genes from A/Michigan/105/2025. Internal genes PB2, PA, NP, M & NS from A/Puerto Rico/8/1934.																											
		<table border="1"> <thead> <tr> <th>Gene</th> <th>A/Puerto Rico/8/1934</th> <th>A/Michigan/105/2025</th> </tr> </thead> <tbody> <tr> <td>HA</td> <td></td> <td>+</td> </tr> <tr> <td>NA</td> <td></td> <td>+</td> </tr> <tr> <td>PB2</td> <td>+</td> <td></td> </tr> <tr> <td>PB1</td> <td></td> <td>+</td> </tr> <tr> <td>PA</td> <td>+</td> <td></td> </tr> <tr> <td>NP</td> <td>+</td> <td></td> </tr> <tr> <td>M</td> <td>+</td> <td></td> </tr> <tr> <td>NS</td> <td>+</td> <td></td> </tr> </tbody> </table>	Gene	A/Puerto Rico/8/1934	A/Michigan/105/2025	HA		+	NA		+	PB2	+		PB1		+	PA	+		NP	+		M	+		NS	+	
Gene	A/Puerto Rico/8/1934	A/Michigan/105/2025																											
HA		+																											
NA		+																											
PB2	+																												
PB1		+																											
PA	+																												
NP	+																												
M	+																												
NS	+																												
Final HA titer for A/Michigan/105/2025 SAN-049A = 10240																													
HA titers were determined using 1.0% guinea pig red blood cells at room temperature.																													
HA-HPLC showed 2.5x increase compared to the original wildtype virus																													

Prepared by:

Approved by:

Amanda Thomas
Scientist
Flu Reassortant Lab
Manufacturing Sciences, Analytics, and
Technology
Swiftwater, PA, USA

Kelly Weaver, PhD
Site Seed SPP
Flu Reassortant Lab
Manufacturing Sciences, Analytics, and
Technology
Swiftwater, PA, USA